Phenylbutazone-obl tab 150mg 20 pieces


Phenylbutazone-obl tab 150mg 20 pieces



Active substance:
1 tablet contains: 150 mg of phenylbutazone ;.
Potato starch, sodium hydrogencarbonate, magnesium stearate, colloidal silicon dioxide (Aerosil), talc, croscarmellose sodium (primelloza).
Tablets white or white with yellowish tinge ploskotsilindricheskoy forms color with the notch and chamfer. At the turn of the white or white with a yellowish tint.
Product form:
Tablets of 150 mg.
At 10 or 20 tablets in blisters of PVC film and aluminum foil printed patent.
1, 2, 3, 4 or 5 contour cell packages together with instructions for use placed in a pile of cardboard. Packs placed in multipacks.
hypersensitivity; complete or partial combination of asthma, recurrent nasal polyposis and paranasal sinuses and intolerance to acetylsalicylic acid and other non-steroidal anti-inflammatory drugs (including history); erosive-ulcerous lesions of the gastrointestinal tract in the acute stage (gastric ulcer and 12 duodenal ulcer, ulcerative colitis, peptic ulcer), bone marrow depression, asthma, chronic heart failure, or pulmonary heart disease, severe liver and / or renal insufficiency ( creatinine clearance less than 30 mL / min), since the aortocoronary bypass surgery; progressive renal disease, active liver disease, confirmed by hyperkalemia, pregnancy (III trimester), active gastrointestinal bleeding, inflammatory bowel disease, children up to 12 years.
Precautions: hyperbilirubinemia, asthma, chronic heart failure, edema, hypertension, hemophilia, hypocoagulation, liver failure, chronic renal failure, hearing loss, the pathology of the vestibular apparatus, blood diseases, diabetes mellitus, systemic lupus erythematosus, polymyalgia rheumatica, temporal arteritis , ulcerative diseases of the gastrointestinal tract, disease, ischemic heart disease, cerebrovascular disease, dyslipidemia / giperlipide Ia, peripheral artery disease, smoking, creatinine clearance less than 60 mL / min, ulcerative lesions of the gastrointestinal tract in the history, the presence of Helicobacter pylori infection, advanced age, long-term use of non-steroidal anti-inflammatory drugs, alcoholism, severe somatic disorders, simultaneous reception of oral corticosteroids ( including prednisone), anticoagulants (including warfarin), antiplatelet agents (including acetylsalicylic acid, clopidogrel), selective serotonin reuptake inhibitors (in .ch. citalopram, fluoxetine, paroxetine, sertraline), I-II trimester of pregnancy, lactation.
150 mg
Inflammatory and degenerative diseases of the musculoskeletal system: rheumatoid, arthritic, psoriatic arthritis, ankylosing spondylitis (Bechterew’s disease), osteoarthritis.
Pain: bursitis, tenosynovitis, arthralgia, myalgia, neuralgia, toothache and headache (including migraine), pain, tuberculosis, pain, trauma, burns.
It is intended for symptomatic therapy, reduce pain and inflammation at the time of use, does not affect the progression of the disease.
Interaction with other drugs
Enhances the action of anticoagulants, antiplatelet agents, fibrinolytic agents, the side effects of glucocorticoids and mineralocorticoids, estrogen, morphine, p-aminosalicylic acid, penicillin, hypoglycemic effect of sulfonylurea derivatives.
Reduces the efficiency of uricosuric, antihypertensive drugs and diuretics.
Increases concentration of lithium in blood preparations, methotrexate.
Inductors microsomal oxidation in the liver (phenytoin, ethanol, barbiturates, rifampicin, tricyclic antidepressants) increase the production of active hydroxylated metabolites.
Antacids colestyramine and reduce absorption.
Myelotoxic drugs increase the expression gematotoksichnosti drug.
Symptoms: cyanosis of the fingertips, lips, body skin, dizziness, headache, increased or decreased blood pressure, hyperventilation, dizziness, children – myoclonic seizures, nausea, vomiting, abdominal pain, hemorrhage, liver and kidney function .
Treatment: gastric lavage, administration of activated charcoal, symptomatic therapy aimed at maintaining vital functions. Forced diuresis and hemodialysis ineffective.
pharmachologic effect
Pharmacological group:
Nonsteroidal anti-inflammatory drugs.
Pharmacological properties:
Nonsteroidal anti-inflammatory drug; anti-inflammatory, analgesic and antipyretic effects associated with inhibition of cyclooxygenase 1 (TSOG1) and cyclooxygenase 2 (TSOG2) regulating the synthesis of prostaglandins. Shows uricosuric action.
At intake absorption – high; Bioavailability – 85-90%, is reduced by chronic administration. The time to reach maximum concentration (TCmax) – 1-2 hours Connection to plasma proteins -. 95%.
It is metabolized in the liver to form two major metabolites. The half-life (T1 / 2) -. 18-24 h excreted by the kidneys 70% (5% unchanged) through the gastro-intestinal tract – 30% as a metabolite, is released in large quantities in breast milk.
Conditions of supply of pharmacies
By prescription.
side effects
From the digestive system: dyspepsia, NSAID-gastropathy, abdominal pain, nausea, vomiting, heartburn, diarrhea, or constipation; during prolonged use at high doses – ulceration of mucosa of the gastrointestinal tract, aphthous stomatitis, glossitis, erosive esophagitis, hemorrhage (gastrointestinal, gingival, hemorrhoids), the liver functions.
Cardio-vascular system: increased blood pressure, tachycardia.
From the nervous system: headache, dizziness, somnolence, depression, agitation.
From the senses: hearing loss, tinnitus.
From the side of hematopoiesis: agranulocytosis, leukopenia, anemia, thrombocytopenia.
Allergic reactions: skin rash, pruritus, urticaria, bronchoconstriction, edema syndrome, angioedema.
Other: increased sweating, uterine bleeding.
special instructions
During treatment requires monitoring picture peripheral blood and functional state of the liver and kidneys.
If necessary, definition of 17-ketosteroids drug should be discontinued 48 hours before the study.
During the treatment should refrain from activities potentially hazardous activities that require attention and speed of mental and motor responses. To reduce the risk of adverse effects from the gastrointestinal tract should use the lowest effective dose of the lowest possible short course.
Storage conditions
In a dry, dark place at a temperature not higher than 25 C. Keep out of reach of children.
Dosing and Administration
Inside, adults, 150 mg during or after meals 3-4 times a day. Children from 12 years 75 mg up to 4 times per day. The duration of therapy is determined by the severity of the condition.
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg


There are no reviews yet.

Add your review